| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
The COVID-19 pandemic might have put a damper on testing for sexually transmitted infections (STIs)—in particular, chlamydia and gonorrhea—but not on the rate of infections, found an analysis published in May. The study, published in the American Journal of Preventive Medicine, concluded that stay-at-home orders early in the pandemic likely led to a 40% decrease in testing—though not necessarily in STI prevalence. “We’ve been losing the battle [against STIs] for six years, and COVID made it harder,” said Harvey W. Kaufman, M.D., senior medical director for Quest Diagnostics and an author of the study.
On this week’s Tech Nation, Moira speaks with DR. HARVEY KAUFMAN, the Senior Medical Director of Quest Diagnostics, about how the use or delay of medical tests reveals about the health status of the US.
With the pandemic pressuring testing demand, lab stewardship programs can help with decision making and actionable insights to make the right testing decisions for patients, leading to better quality outcomes. By Lee Hilborne, MD, MPH.
Local health care providers and diagnostics companies are feeling the squeeze as demand increases for Covid-19 testing amid fears of the more-contagious Delta variant. The pattern has also affected companies that manufacture and process the tests, such as Quest Diagnostics. As of this week the Secaucus, N.J.–based company has performed 44.5 million tests since the beginning of the pandemic.
If you're not sure what's causing your symptoms, you might want to start with an allergy test first. "When it comes to allergies, knowledge is power," says Jeffrey S. Dlott, MD, MS, senior medical director for Quest Diagnostics.